4basebio PLC (AIM: 4BB)

Market Cap	185.68M
Revenue (ttm)	506.00K
Net Income (ttm)	-7.67M
Shares Out	12.81M
EPS (ttm)	-0.62
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	591
Open	1,400.00
Previous Close	1,450.00
Day's Range	1,400.00 - 1,400.00
52-Week Range	492.00 - 1,820.00
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 20, 2024

About 4basebio

4basebio PLC engages in the research, development, manufacturing, and commercialization of synthetic DNA and RNA products, and targeted non-viral vector solutions in the United States, Europe, and internationally. The company offers AVV and Lentivirus manufacturing services for use in gene therapies and vaccines. It also offers access to its targeted non-viral delivery platform, Hermes. The company was formerly known as 4basebio UK Societas and changed its name to 4basebio PLC in July 2021. 4basebio PLC was founded in 2008 and is based in Cambr...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2008
• Employees: 84
• Stock Exchange: London Stock Exchange AIM
• Ticker Symbol: 4BB

Financial Performance

In 2023, 4basebio's revenue was 506,000, an increase of 88.81% compared to the previous year's 268,000. Losses were -7.67 million, 48.8% more than in 2022.